{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:19Z","timestamp":1792431919515,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jpba.2019.05.022","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T11:23:25Z","timestamp":1557573805000},"page":"395-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["The contamination of valsartan and other sartans, part 1: New findings"],"prefix":"10.1016","volume":"172","author":[{"given":"Fritz","family":"S\u00f6rgel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Abdel-Tawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Bidmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wohlfart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Besa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Holzgrabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.05.022_bib0005","series-title":"Foye\u2019s Principles of Medicinal Chemistry","first-page":"747","article-title":"Agents affecting the renin-angiotensin pathway and calcium blockers","author":"Herold","year":"2013"},{"key":"10.1016\/j.jpba.2019.05.022_bib0010","series-title":"Discovery and Development of Angiotensin Receptor Blockers","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0015","series-title":"Statistics by Health Insurance Companies of Medicines Used in Germany","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0020","series-title":"Valsartan: chargenbezogener R\u00fcckruf valsartanhaltiger Arzneimittel, deren Wirkstoff von dem chinesischen Hersteller Zhejiang Huahai Pharmaceutical produziert wurde Pressemitteilung 5\/18","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0025","series-title":"First report of EMA about contamination of valsartan tablets from Zhejiang Huahai","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0030","series-title":"International Agency for Research on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","author":"World Health Organization (WHO)","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0035","series-title":"U.S. Environemental Protection Agency, Integrated Risk Information System (IRIS), Chemical Assessment Summary N-nitrosodiemethylamine, CASRN 62-75-9","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0040","unstructured":"U.S. Environemental Protection Agency, Technical Fact Sheet - N-nitroso-diemethylamine (NDMA) https:\/\/www.epa.gov\/sites\/production\/files\/2014-03\/documents\/ffrrofactsheet_contaminant_ndma_january2014_final.pdf (Accessed 22 January, 2019)."},{"key":"10.1016\/j.jpba.2019.05.022_bib0045","series-title":"Over 27,000 Patients Affected by Warning Over Valsartan. The Government Has Not Ruled Out Obtaining Emergency Supplies","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0050","series-title":"FDA UpdateFDA Updates on Angiotensin II Receptor Blocker (ARB) Recalls Including Valsartan, Losartan and Irbesartan","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0055","series-title":"Number of Countries Where Recalls Were Made and FDA\u2019s Reaction","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0060","series-title":"Valsartan -Disponibilit\u00e9 Des M\u00e9dicaments \u00e0 Base De Valsartan Et Autres Sartans En France","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0065","article-title":"ZL findet NDMA in tabletten","volume":"30","author":"Abdel-Tawab","year":"2018","journal-title":"PZ Pharm. Ztg."},{"key":"10.1016\/j.jpba.2019.05.022_bib0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.022_bib0075","first-page":"362","article-title":"Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: danish nationwide cohort study","volume":"12","author":"Potteg\u00e5rd","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.jpba.2019.05.022_bib0080","series-title":"New Contamination NDEA Found","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0085","unstructured":"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm620499.htm (Accessed 22 January 2019)."},{"key":"10.1016\/j.jpba.2019.05.022_bib0090","series-title":"WHO Model Lists of Essential Medicines","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0095","series-title":"The Sartan Contamination Story.D. Lowe","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0100","series-title":"Ad-hoc Projects of the OMCL Network. Methods for Determination of NDMA and NDEA in Sartans","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0105","series-title":"European committee for standardization. CEN\/TC 52 - Safety of Toys - Part 12: N-Nitrosamines and N-nitrosatable Substances (EN 71-12:2016)","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0110","first-page":"50","article-title":"Noch mehr nitrosamine","volume":"159","author":"Buschmann","year":"2019","journal-title":"Apoth."},{"key":"10.1016\/j.jpba.2019.05.022_bib0115","series-title":"Warning Letter Zhejiang Huahai Pharmaceutical 11\/29\/18","year":"2018"},{"issue":"Apr","key":"10.1016\/j.jpba.2019.05.022_bib0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2019.04.035","article-title":"The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities","volume":"172","author":"Scherf-Clavel","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.022_bib0125","series-title":"N,N-Dimethylpentanamide RN: 6225-06-5,in TOXNET- Toxicology Data Network","year":"2019"},{"key":"10.1016\/j.jpba.2019.05.022_bib0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0005-2736(88)90201-5","article-title":"Modulation of water transport in human red cells: effect of urea","volume":"940","author":"Toon","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpba.2019.05.022_bib0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/tc.2003.005579","article-title":"The case of the disappearing nitrosamines: a potentially global phenomenon","volume":"1","author":"Gray","year":"2004","journal-title":"Tob. Control"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519302183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519302183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:58:46Z","timestamp":1760000326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519302183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"alternative-id":["S0731708519302183"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.022","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contamination of valsartan and other sartans, part 1: New findings","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.04.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}